- €20 million EIB venture-debt loan, backed by InvestEU, to BioLamina
- Financing will scale and optimise manufacturing of full-length human recombinant laminins (Biolaminin® substrates) for clinical-grade cell culture
- Laminin substrates support scalable production of consistent, high-quality cells and enable animal-origin-free drug-safety testing
- Intended applications include cell therapies targeting type 1 diabetes, Parkinson's, heart failure, acute liver failure and cancer
Financing
The European Investment Bank is lending €20 million to Swedish biotech BioLamina in the form of venture debt, backed by the InvestEU programme; this long-term financing complements venture capital and limits immediate dilution for existing shareholders.
Use of funds
Proceeds will be used to scale and optimise manufacturing of full-length human recombinant laminins, expand the product portfolio and reinforce the company’s technology and production capabilities.
Technology and applications
BioLamina’s defined, animal-origin-free laminin substrates enable controlled growth and differentiation of pluripotent stem cells and primary cells, supporting consistent, clinical-grade cell production and more reliable, animal-free drug-safety testing.
Strategic impact
The operation is intended to strengthen Europe’s life-sciences capacity and support development of next-generation cell therapies for conditions including type 1 diabetes, Parkinson’s disease, heart failure, acute liver failure and cancer.
